How Esbriet may help preserve more lung function by slowing disease progression

Esbriet may help preserve more of your lung function by slowing disease progression

Lost lung function cannot be restored. However, Esbriet may help preserve more of your lung function by slowing the progression of the disease.

  • At the end of a 1-year clinical study of people with IPF, more people who took Esbriet had stable lung function, compared with people who did not take Esbriet
With Esbriet, 23% of people had stable lung function vs 10% of people without Esbriet who had stable lung function
  • One 72-week trial showed similar results. Another 72-week trial did not show a significant difference between patients who took Esbriet and those who did not

How lung function was measured in trials

In the clinical studies, the effect of Esbriet on lung function (how well the lungs work) was measured by forced vital capacity (FVC). FVC is the amount of air you can exhale with force after you inhale as deeply as possible.

Esbriet may help you maintain more of your breathing capacity

  • In a 1-year clinical study of people with IPF, the average FVC decline in people taking Esbriet was nearly half as much as in people not taking Esbriet (193 mL difference in FVC)
    • People taking Esbriet had an average decline of 235 mL in FVC, compared with a 428 mL decline for people who did not take Esbriet
Less decline in FVC Volume for People Taking Esbriet
  • There were also two 72-week studies that monitored changes in FVC. In one of the 72-week studies, people taking Esbriet had an average decline of 318 mL in FVC, compared with a 475 mL decline for people who did not take Esbriet. The average treatment difference was 157 mL
  • The other 72-week study did not show a significant difference between the two groups

Key facts about Esbriet® (pirfenidone)

  • Esbriet is a prescription medicine indicated for the treatment of idiopathic pulmonary fibrosis (IPF)
  • Three clinical studies evaluating the safety and effectiveness of Esbriet were reviewed by the FDA
  • Esbriet may cause serious side effects
  • Esbriet has been used in more than 31,000 patients worldwide

IPF is irreversible, so it’s important to take action today

  • Slowing disease progression can be an important goal of IPF treatment
  • Starting and staying on Esbriet as prescribed by your doctor can be important to help preserve more lung function by slowing disease progression

Learn more about why lung function matters >

TAKING ESBRIET

Taking Esbriet

See dosing information, tips for sticking to a schedule, and ways to manage possible side effects.

QUESTIONS ABOUT ESBRIET

Questions about Esbriet

See a list of answers to frequently asked questions about IPF treatment with Esbriet.

PATIENT SUPPORT PROGRAM

Esbriet Inspiration Program

Receive ongoing support and materials from the Esbriet® Inspiration Program™ to help you manage IPF.